We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 13 and set a price target of ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...